• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Amyris Inc. (Amendment)

    8/3/23 9:03:25 AM ET
    $AMRS
    Major Chemicals
    Industrials
    Get the next $AMRS alert in real time by email
    SC 13D/A 1 d515038dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 10)*

     

     

    AMYRIS, INC.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    03236M200

    (CUSIP Number)

    Barbara Hager

    c/o Foris Ventures, LLC

    1180 San Carlos Avenue, #717

    San Carlos, CA 94070

    650-384-0240

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    COPY TO:

    Jon M. Novotny, Esq.

    c/o Goodwin Procter LLP

    Three Embarcadero Center

    San Francisco, CA 94111

    (415) 733-6000

    August 2, 2023

    (Date of Event Which Requires Filing of This Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box  ☐

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


      1    

      NAME OF REPORTING PERSON

     

      Foris Ventures, LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS

     

      OO

      5  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      120,480,436(1)

         8   

      SHARED VOTING POWER

     

      0

         9   

      SOLE DISPOSITIVE POWER

     

      120,480,436(1)

       10   

      SHARED DISPOSITIVE POWER

     

      0

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      120,480,436(1)

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 11 EXCLUDES CERTAIN SHARES

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW

     

      29.9%(2)

    14  

      TYPE OF REPORTING PERSON

     

      OO

     

    (1)

    Consists of (i) 87,268,358 shares of common stock, par value $0.0001 per share (“Common Stock”), of Amyris, Inc. (the “Company”) currently outstanding and held by Foris Ventures, LLC (“FV”), (ii) 21,166,042 shares of Common Stock issuable to FV upon conversion of the total amount of indebtedness outstanding, including accrued and unpaid interest as of August 2, 2023, under that certain Amended and Restated Loan and Security Agreement, dated as of October 28, 2019 (as it may be further amended, restated or otherwise modified, the “2019 LSA”), by and among the Company, FV, as lender, and the other parties thereto; (iii) 2,046,036 shares of Common Stock issuable to FV upon exercise of a warrant issued to FV on September 13, 2022 (the “September 2022 Warrant”) in connection with that certain Loan and Security Agreement, dated as of September 13, 2022 (as it may be amended, restated or otherwise modified, the “2022 LSA”), by and among the Company, FV, as lender, and the other parties thereto; and (iv) 10,000,000 shares of Common Stock issuable to FV upon exercise of a warrant issued to FV on December 30, 2022 (the “December 2022 Warrant” and together with the September 2022 Warrant, collectively the “2022 Warrants”). As of August 2, 2023, 16,680,334 shares of Common Stock are issuable upon conversion of the indebtedness outstanding under the 2019 LSA in respect of an outstanding principal amount of $50.0 million and 4,485,708 shares of Common Stock are issuable upon conversion of accrued and unpaid interest of $13.5 million, reflecting a fixed conversion price of $3.00 per share of Common Stock. Barbara Hager, the manager of FV, may be deemed to have sole power to vote and dispose of these securities. The 2019 LSA bears interest at 6.0% per annum, subject to certain default interest provisions in the event of a default under the 2019 LSA; interest accrues until the maturity date of July 1, 2024. The Vallejo Ventures Trust U/T/A 2/12/96 (“VVT”), the member of FV, may be deemed to have sole power to vote and dispose of these securities, and L. John Doerr (“John Doerr”) and Ann Doerr, the trustees of VVT, and Barbara Hager, the special trustee of VVT, may be deemed to have shared power to vote and dispose of these securities.

    (2)

    The percentage calculation is based on a total of 402,597,692 shares of Common Stock, which amount consists of (i) 369,385,614 shares of Common Stock issued and outstanding as of May 5, 2023 based on the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023, as filed with the U.S. Securities and Exchange Commission (the “SEC”) on May 10, 2023, (ii) 21,166,042 shares of Common Stock issuable to FV upon conversion of the indebtedness outstanding under the 2019 LSA, including accrued and unpaid interest as of August 2, 2023 and (iii) 12,046,036 shares of Common Stock issuable to FV upon exercise of the 2022 Warrants.


      1    

      NAME OF REPORTING PERSON

     

      The Vallejo Ventures Trust U/T/A 2/12/96

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS

     

      OO

      5  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      California

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      120,481,003(1)

         8   

      SHARED VOTING POWER

     

      0

         9   

      SOLE DISPOSITIVE POWER

     

      120,481,003(1)

       10   

      SHARED DISPOSITIVE POWER

     

      0

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      120,481,003(1)

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 11 EXCLUDES CERTAIN SHARES

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

      29.9%(2)

    14  

      TYPE OF REPORTING PERSON

     

      OO

     

    (1)

    Consists of (i) 87,268,358 shares of Common Stock currently outstanding and held by FV, (ii) 21,166,042 shares of Common Stock issuable to FV upon conversion of the indebtedness outstanding under the 2019 LSA, including accrued and unpaid interest as of August 2, 2023, (iii) 12,046,036 shares of Common Stock issuable to FV upon exercise of the 2022 Warrants and (iv) 567 shares of Common Stock held directly by VVT. VVT, the member of FV, may be deemed to have sole power to vote and dispose of these securities, and John Doerr and Ann Doerr, the trustees of VVT, and Barbara Hager, the special trustee of VVT, may be deemed to have shared power to vote and dispose of the securities held by FV and VVT.

    (2)

    The percentage calculation is based on a total of 402,597,692 shares of Common Stock, which amount consists of (i) 369,385,614 shares of Common Stock issued and outstanding as of May 5, 2023 based on the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023, as filed with the SEC on May 10, 2023, (ii) 21,166,042 shares of Common Stock issuable to FV upon conversion of the indebtedness outstanding under the 2019 LSA, including accrued and unpaid interest as of August 2, 2023 and (iii) 12,046,036 shares of Common Stock issuable to FV upon exercise of the 2022 Warrants.


      1    

      NAME OF REPORTING PERSON

     

      L. John Doerr

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS

     

      OO

      5  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      140,711(1)

         8   

      SHARED VOTING POWER

     

      124,076,819(2)

         9   

      SOLE DISPOSITIVE POWER

     

      140,711(1)

       10   

      SHARED DISPOSITIVE POWER

     

      124,076,819(2)

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      124,217,530(3)

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 11 EXCLUDES CERTAIN SHARES

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

      30.8%(4)

    14  

      TYPE OF REPORTING PERSON

     

      IN

     

    (1)

    Consists of (i) 46,047 shares of Common Stock held by John Doerr, (ii) 14,664 shares of Common Stock issuable to John Doerr upon exercise of options within 60 days of August 2, 2023 and (iii) 80,000 shares of Common Stock issuable to John Doerr upon the vesting of restricted stock units within 60 days of August 2, 2023.

    (2)

    Consists of (i) 87,268,358 shares of Common Stock currently outstanding and held by FV, (ii) 21,166,042 shares of Common Stock issuable to FV upon conversion of the indebtedness outstanding under the 2019 LSA, including accrued and unpaid interest as of August 2, 2023, (iii) 12,046,036 shares of Common Stock issuable to FV upon exercise of the 2022 Warrants, (iv) 567 shares of Common Stock held by VVT, (v) 9,648 shares of Common Stock held by Clarus, LLC, (vi) 248,304 shares of Common Stock held by Kleiner Perkins Caufield & Byers XII, LLC, (vii) 4,531 shares of Common Stock held by KPCB XII Founders Fund, LLC, and (viii) 3,333,333 shares of Common Stock held by Perrara Ventures, LLC (“Perrara”). John Doerr is a trustee of VVT, which is the member of FV and Clarus, LLC. Mr. Doerr may be deemed to have shared power to vote and dispose of shares beneficially owned by FV, VVT and Clarus, LLC. The Managing Member of Kleiner Perkins Caufield & Byers XII, LLC is KPCB XII Associates, LLC, of which Mr. Doerr is the managing member. The Managing Member of KPCB XII Founders Fund, LLC is KPCB XII Associates, LLC, of which Mr. Doerr is the managing member. Mr. Doerr indirectly holds all of the membership interests in Perrara. Mr. Doerr disclaims beneficial ownership of all securities held by entities affiliated with him except to the extent of his pecuniary interest therein.

    (3)

    Consists of (i) 87,268,358 shares of Common Stock currently outstanding and held by FV, (ii) 21,166,042 shares of Common Stock issuable to FV upon conversion of the indebtedness outstanding under the 2019 LSA, including accrued and unpaid interest as of August 2, 2023, (iii) 12,046,036 shares of Common Stock issuable to FV upon exercise of the 2022 Warrants, (iv) 567 shares of Common Stock held by VVT, (v) 9,648 shares of Common Stock held by Clarus, LLC, (vi) 248,304 shares of Common Stock held by Kleiner Perkins Caufield & Byers XII, LLC, (vii) 4,531 shares of Common Stock held by KPCB XII Founders Fund, LLC, (viii) 3,333,333 shares of Common Stock held by Perrara, (ix) 46,047 shares of Common Stock held by John Doerr, (x) 14,664 shares of Common Stock issuable to Mr. Doerr upon exercise of options within 60 days of August 2, 2023, and (xi) 80,000 shares of Common Stock issuable to John Doerr upon the vesting of restricted stock units within 60 days of August 2, 2023. John Doerr is a trustee of VVT, which is the member of FV and Clarus, LLC. Mr. Doerr may be deemed to have shared power to vote and dispose of shares beneficially owned by FV, VVT and Clarus, LLC. The Managing Member of Kleiner Perkins Caufield & Byers XII, LLC is KPCB XII Associates, LLC, of which Mr. Doerr is the managing member. The Managing Member of KPCB XII Founders Fund, LLC is KPCB XII Associates, LLC, of which Mr. Doerr is the managing member. Mr. Doerr indirectly holds all of the membership interests in Perrara. Mr. Doerr disclaims beneficial ownership of all securities held by entities affiliated with him except to the extent of his pecuniary interest therein.

    (4)

    The percentage calculation is based on a total of 402,692,356 shares of Common Stock, which amount consists of (i) 369,385,614 shares of Common Stock issued and outstanding as of May 5, 2023 based on the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023, as filed with the SEC on May 10, 2023, (ii) 21,166,042 shares of Common Stock issuable to FV upon conversion of the indebtedness outstanding under the 2019 LSA, including accrued and unpaid interest as of August 2, 2023, (iii) 12,046,036 shares of Common Stock issuable to FV upon exercise of the 2022 Warrants, (iv) 14,664 shares of Common Stock issuable to John Doerr upon the exercise of stock options exercisable for Common Stock within 60 days of August 2, 2023, and (v) 80,000 shares of Common Stock issuable to John Doerr upon the vesting of restricted stock units within 60 days of August 2, 2023.


      1    

      NAME OF REPORTING PERSON

     

      Ann Doerr

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS

     

      OO

      5  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      0

         8   

      SHARED VOTING POWER

     

      120,481,003(1)

         9   

      SOLE DISPOSITIVE POWER

     

      0

       10   

      SHARED DISPOSITIVE POWER

     

      120,481,003(1)

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      120,481,003(1)

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 11 EXCLUDES CERTAIN SHARES

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

      29.9%(2)

    14  

      TYPE OF REPORTING PERSON

     

      IN

     

    (1)

    Consists of (i) 87,268,358 shares of Common Stock currently outstanding and held by FV, (ii) 21,166,042 shares of Common Stock issuable to FV upon conversion of the indebtedness outstanding under the 2019 LSA, including accrued and unpaid interest as of August 2, 2023, (iii) 12,046,036 shares of Common Stock issuable to FV upon exercise of the 2022 Warrants and (iv) 567 shares of Common Stock held directly by VVT. VVT, the member of FV, may be deemed to have sole power to vote and dispose of these securities, and John Doerr and Ann Doerr, the trustees of VVT, and Barbara Hager, the special trustee of VVT, may be deemed to have shared power to vote and dispose of the securities held by FV and VVT.

    (2)

    The percentage calculation is based on a total of 402,597,692 shares of Common Stock, which amount consists of (i) 369,385,614 shares of Common Stock issued and outstanding as of May 5, 2023 based on the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023, as filed with the SEC on May 10, 2023, (ii) 21,166,042 shares of Common Stock issuable to FV upon conversion of the indebtedness outstanding under the 2019 LSA, including accrued and unpaid interest as of August 2, 2023 and (iii) 12,046,036 shares of Common Stock issuable to FV upon exercise of the 2022 Warrants.


      1    

      NAME OF REPORTING PERSON

     

      Barbara Hager

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS

     

      OO

      5  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      123,823,984(1)

         8   

      SHARED VOTING POWER

     

      0

         9   

      SOLE DISPOSITIVE POWER

     

      123,823,984(1)

       10   

      SHARED DISPOSITIVE POWER

     

      0

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      123,823,984(1)

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 11 EXCLUDES CERTAIN SHARES

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

      30.8%(2)

    14  

      TYPE OF REPORTING PERSON

     

      IN

     

    (1)

    Consists of (i) 87,268,358 shares of Common Stock currently outstanding and held by FV, (ii) 21,166,042 shares of Common Stock issuable to FV upon conversion of the indebtedness outstanding under the 2019 LSA, including accrued and unpaid interest as of August 2, 2023, (iii) 12,046,036 shares of Common Stock issuable to FV upon exercise of the 2022 Warrants, (iv) 567 shares of Common Stock held directly by VVT, (v) 9,648 shares of Common Stock held by Clarus, LLC, and (vi) 3,333,333 shares of Common Stock held by Perrara. Barbara Hager, the manager of FV and Clarus, LLC, may be deemed to have sole power to vote and dispose of these securities. VVT, the member of FV, may be deemed to have sole power to vote and dispose of these securities, and John Doerr and Ann Doerr, the trustees of VVT, and Barbara Hager, the special trustee of VVT, may be deemed to have shared power to vote and dispose of the securities held by FV and VVT.

    (2)

    The percentage calculation is based on a total of 402,597,692 shares of Common Stock, which amount consists of (i) 369,385,614 shares of Common Stock issued and outstanding as of May 5, 2023 based on the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023, as filed with the SEC on May 10, 2023, (ii) 21,166,042 shares of Common Stock issuable to FV upon conversion of indebtedness outstanding under the 2019 LSA, including accrued and unpaid interest as of August 2, 2023 and (iii) 12,046,036 shares of Common Stock issuable to FV upon exercise of the 2022 Warrants.


    This Amendment No. 10 (“Amendment No. 10”) to Schedule 13D amends the statement on Schedule 13D filed with the United States Securities and Exchange Commission on October 30, 2017, as amended by Amendment No. 1 thereto filed on August 28, 2018, Amendment No. 2 thereto filed on July 18, 2019, Amendment No. 3 thereto filed on September 8, 2022, Amendment No. 4 thereto filed on September 15, 2022, Amendment No. 5 thereto filed on January 9, 2023, Amendment No. 6 thereto filed on March 17, 2023, Amendment No. 7 thereto filed on May 24, 2023, Amendment No. 8 thereto filed on June 9, 2023 and Amendment No. 9 thereto filed on June 30, 2023 (collectively and as amended, the “Schedule 13D”), relating to the Common Stock. This Amendment No. 10 is being filed by Foris Ventures, LLC, Vallejo Ventures Trust, L. John Doerr, Ann Doerr, and Barbara Hager (collectively, the “Reporting Persons”).

    The Items below amend the information disclosed under the corresponding Items of the Schedule 13D as described below. Except as specifically provided herein, this Amendment No. 10 does not modify any of the information previously reported in the Schedule 13D.

    ITEM 4. PURPOSE OF TRANSACTION.

    Item 4 of the Schedule 13D is supplemented by the following:

    Muirisc Loan Agreement

    On August 2, 2023, the Company, certain of the Company’s subsidiaries (the “Subsidiary Guarantors”) and Muirisc, LLC (“Muirisc”), an affiliate of FV, as lender, entered into a Loan and Security Agreement (the “Muirisc Loan Agreement”) to make available to the Company a secured term loan facility in an aggregate principal amount of up to $20 million (the “Loan Facility”), which was drawn down in full on August 2, 2023.

    The Loan Facility matures on October 31, 2024. Loans under the Loan Facility will bear interest at a rate of 12% per annum. Interest is capitalized when due, on the first business day of each calendar quarter beginning with the calendar quarter starting after the advance date of any advance.

    The obligations under the Loan Facility are (i) guaranteed by the Subsidiary Guarantors, and (ii) secured by a perfected first lien security interest in substantially all of the assets of the Company and the Subsidiary Guarantors, in each case subject to certain limitations and exclusions.

    Prepayment of the outstanding amounts under the Loan Facility will be required upon the occurrence of a change of control of the Company, as specified in the Muirisc Loan Agreement. In addition, the Company may at its option prepay the outstanding principal amount of the loans under the Loan Facility before the maturity date of such loans without the incurrence of a prepayment fee.

    The representations, covenants, and events of default in the Muirisc Loan Agreement are customary for financing transactions of this nature. If any payment under the Loan Facility is not made when due, an amount equal to 3% of the past due amount shall be payable on demand. In addition, upon the occurrence and during the continuation of an event of default, all principal, interest and other obligations under the Loan Facility shall bear interest at 12% per annum plus 1%. The Muirisc Loan Agreement includes customary affirmative and negative covenants relating to the operations of the Company and its subsidiaries as well as information and financial covenants and events of default. These include, without limitation, the following: (i) the Company shall provide the Lender (a) on the last business day of each week with a 13-week cash flow forecast for the Company and the Subsidiary Guarantors, including consolidated balance sheets, statements of income, and cash flow forecasts, and (b) within 30 days after the end of each calendar quarter, aged listings of accounts receivable and accounts payable; (ii) as of the last day of each fiscal quarter, the Company and its consolidated entities shall have revenue (determined in accordance with GAAP) of not less than $150,000,000 on a trailing 12 month basis; (iii) on the last Business Day of each week, the Company and the Subsidiary Guarantors shall have, on a consolidated basis, liquidity calculated as (a) unrestricted, unencumbered cash and cash equivalents denominated in dollars in one or more deposit accounts located in the United States, plus (b) any additional amount of available credit, borrowings, or investments readily convertible to cash to the extent necessary, so that the sum of the amounts described in clauses (a) and (b) is not less than $2,000,000; (iv) commencing on July 17, 2023, and on a weekly basis thereafter, the Company shall, or shall cause its financial advisors to, prepare and deliver to the Lender cash flow projections, in form and methodology as previously provided to the Lender, showing that the Company and the other Subsidiary Guarantors have adequate liquidity to operate their businesses through and including the calendar year ending December 31, 2023; and (v) it will be an


    event of default if all or any part of Tranche 3 (as defined in the loan agreement by and between DSM Finance B.V. and the Company) is repaid or prepaid on or before April 15, 2024 other than from proceeds of sale of (a) all of the capital stock of Amyris RealSweet, LLC, or (b) the consummation of any sale of any consumer brands from which, in the case of this clause (b), the Company and the Subsidiary Guarantors shall receive at least $75,000,000 in gross proceeds, which must, in each case, be on terms acceptable to the Lender in its absolute discretion.

    General

    The Reporting Persons acquired the securities described in this Schedule for investment purposes and they intend to review their investments in the Company on a continuing basis. In addition, the Reporting Persons intend to participate in the management of the Company through representation on the Company’s board of directors (the “Board”). L. John Doerr and Ryan Panchadsaram, a partner at Foris Ventures, serve as members of the Board. Any actions the Reporting Persons might undertake will be dependent upon the Reporting Persons’ review of numerous factors, including, but not limited to: an ongoing evaluation of the Company’s business, financial condition, operations and prospects; price levels of the Company’s securities; general market, industry and economic conditions; the relative attractiveness of alternative business and investment opportunities; and other future developments.

    On August 3, 2023, the Company announced that it is continuing a strategic review of all aspects of its cost structure under the direction of its Restructuring Committee of the Company’s board of directors, and in connection therewith, the Company continues to explore a range of strategic alternatives, including in or out of court restructuring of its outstanding debt, additional financing and sales of assets. The Reporting Persons have discussed the Muirisc Loan Agreement with the Company’s management and board of directors in connection with such strategic alternatives, including providing additional financing or otherwise supporting such alternatives, including in or out of court restructuring of the Company’s outstanding debt and sales of the Company’s assets, and intend to continue such discussions. The Reporting Persons may also, at any time and from time to time, acquire additional securities of the Company, or retain or sell all or a portion of the securities then held, in the open market or in privately negotiated transactions. In addition, the Reporting Persons may take one or more other actions that relate to or would result in any matter referenced in items (a) through (j) of Item 4 of Schedule 13D, alone or with others, including other shareholders or creditors of the Company or other appropriate parties, although the Reporting Persons may change their purpose or formulate different plans or proposals with respect thereto at any time.

    ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.

    Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows:

    (a)-(b)

    The following sets forth, as of the date of this statement, the aggregate number of shares of Common Stock and percentage of Common Stock beneficially owned by each of the Reporting Persons, as well as the number of shares of Common Stock as to which each Reporting Person has the sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition of, or shared power to dispose or to direct the disposition of, as of the date hereof, based on a total of 402,597,692 shares of Common Stock, which amount consists of (i) 369,385,614 shares of Common Stock issued and outstanding as of May 5, 2023 based on the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023, as filed with the SEC on May 10, 2023, (ii) 21,166,042 shares of Common Stock issuable to FV upon conversion of the indebtedness outstanding under the 2019 LSA, including accrued and unpaid interest as of August 2, 2023 and (iii) 12,046,036 shares of Common Stock issuable to FV upon exercise of the 2022 Warrants.

    For the purposes of calculating John Doerr’s beneficial ownership only, the percent of class set forth below is based on a total of 402,692,356 based on the Company’s shares of Common Stock, which amount consists of (i) 369,385,614 shares of Common Stock issued and outstanding as of May 5, 2023 based on the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023, as filed with the SEC on May 10, 2023, (ii) 21,166,042 shares of Common Stock issuable to FV upon conversion of the indebtedness outstanding under the 2019 LSA, including accrued and unpaid interest as of August 2, 2023, (iii) 12,046,036 shares of Common Stock issuable to FV upon exercise of the 2022 Warrants, (iv) 14,664 shares of Common Stock issuable to John Doerr upon the exercise of stock options exercisable for Common Stock within 60 days of August 2, 2023, and (v) 80,000 shares of Common Stock issuable to John Doerr upon the vesting of restricted stock units within 60 days of August 2, 2023.

     


    Reporting

    Person

       Amount
    beneficially
    owned
         Percent
    of class
        Sole
    power to
    vote or
    to direct
    the vote
         Shared
    power to
    vote or to
    direct
    the vote
         Sole
    power to
    dispose or
    to direct
    the disposition
         Shared
    power to
    dispose or
    to direct
    the disposition
     

    FV

         120,480,436        29.9 %      120,480,436        0        120,480,436        0  

    VVT

         120,481,003        29.9 %      120,481,003        0        120,481,003        0  

    John Doerr

         124,217,530        30.8 %      140,711        124,076,819        140,711        124,076,819  

    Ann Doerr

         120,481,003        29.9 %      0        120,481,003        0        120,481,003  

    Barbara Hager

         123,823,984        30.8 %      123,823,984        0        123,823,984        0  

    The securities reported herein consist of (i) 87,268,358 shares of Common Stock currently outstanding and held by FV, (ii) 21,166,042 shares of Common Stock issuable upon conversion of the indebtedness outstanding under the 2019 LSA, including accrued and unpaid interest as of August 2, 2023, (iii) 12,046,036 shares of Common Stock issuable to FV upon exercise of the 2022 Warrants, (iv) 567 shares of Common Stock held by VVT, (v) 9,648 shares of Common Stock held by Clarus, LLC, (vi) 248,304 shares of Common Stock held by Kleiner Perkins Caufield & Byers XII, LLC and (vii) 4,531 shares of Common Stock held by KPCB XII Founders Fund, LLC, (viii) 3,333,333 shares of Common Stock held by Perrara, (ix) 46,047 shares of Common Stock held by John Doerr, (x) 14,664 shares of Common Stock issuable to John Doerr upon exercise of options within 60 days of August 2, 2023, and (xi) 80,000 shares of Common Stock issuable to John Doerr upon the vesting of restricted stock units within 60 days of August 2, 2023.

    As of August 2, 2023, 16,680,334 shares of Common Stock are issuable upon conversion of the indebtedness outstanding under the 2019 LSA in respect of an outstanding principal amount of $50.0 million and 4,485,708 shares of Common Stock are issuable upon conversion of accrued and unpaid interest of $13.5 million, reflecting a fixed conversion price of $3.00 per share of Common Stock. Barbara Hager, the manager of FV, may be deemed to have sole power to vote and dispose of these securities. The 2019 LSA bears interest at 6.0% per annum, subject to certain default interest provisions in the event of a default under the 2019 LSA; interest is not payable until the maturity date of July 1, 2024.

     

      (c)

    On June 30, 2023, 11,600 restricted stock units previously granted to Mr. Doerr in his capacity as a director of the Company vested in accordance with their terms.

    On August 1, 2023, options to purchase 400 shares of Common Stock previously granted to Mr. Doerr in his capacity as a director of the Company expired for no consideration in accordance with their terms.

    Other than as set forth in this Item 5, the Reporting Persons have not effected any transaction in the Common Stock during the past 60 days.

     

      (d)

    Except as set forth in Item 4 above, no person is known to have the right to receive dividends from, or the proceeds from, the sale of shares identified pursuant to Item 1.

     

      (e)

    Not applicable.

    ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER.

    Item 6 of the Schedule 13D is hereby amended and restated in its entirety as follows:

    The information set forth under Items 4 and 5 and the agreements set forth on the Exhibit attached hereto are incorporated herein by reference. Other than as described herein and in the Schedule 13D, to the best of the knowledge of the Reporting Persons, there are no contracts, arrangements, understandings or relationships (legal or otherwise) between each Reporting Person and any person, with respect to the securities of the Company, including,


    but not limited to, transfer or voting of any of the securities, finder’s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies, including any securities pledged or otherwise subject to a contingency the occurrence of which would give another person voting power or investment power over such securities other than standard default and similar provisions contained in loan agreements.

    ITEM 7. MATERIAL TO BE FILED AS EXHIBITS.

    Item 7 of the Schedule 13D is hereby supplemented as follows:

     

    Exhibit   

    Description

    OO    Loan and Security Agreement, dated August 2, 2023, by and among the Company, the Subsidiary Guarantors and Muirisc, LLC (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on August 2, 2023)


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: August 3, 2023

     

    FORIS VENTURES, LLC
    By:   /s/ Barbara Hager
    Name:   Barbara Hager
    Title:   Manager
    VALLEJO VENTURES TRUST
    By:   /s/ Barbara Hager
    Name:   Barbara Hager
    Title:   Special Trustee
    L. JOHN DOERR
    By:   /s/ L. John Doerr, by Barbara Hager as his attorney in fact
    ANN DOERR
    By:   /s/ Ann Howland Doerr, by Barbara Hager as her attorney in fact
    BARBARA HAGER
    By:   /s/ Barbara Hager
    Get the next $AMRS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AMRS

    DatePrice TargetRatingAnalyst
    5/18/2023$3.10 → $0.65Buy → Hold
    Jefferies
    5/10/2023$4.00 → $1.25Outperform → Market Perform
    TD Cowen
    4/28/2023$1.50Buy
    Canaccord Genuity
    11/10/2022Overweight → Neutral
    JP Morgan
    11/9/2022Outperform → Perform
    Oppenheimer
    8/10/2022$4.00 → $2.00Buy → Neutral
    ROTH Capital
    6/24/2022Neutral
    JP Morgan
    5/25/2022$2.50Neutral
    Piper Sandler
    More analyst ratings

    $AMRS
    SEC Filings

    See more
    • SEC Form S-8 POS filed by Amyris Inc.

      S-8 POS - AMYRIS, INC. (0001365916) (Filer)

      2/9/24 9:14:56 PM ET
      $AMRS
      Major Chemicals
      Industrials
    • SEC Form S-8 POS filed by Amyris Inc.

      S-8 POS - AMYRIS, INC. (0001365916) (Filer)

      2/9/24 9:11:00 PM ET
      $AMRS
      Major Chemicals
      Industrials
    • SEC Form S-8 POS filed by Amyris Inc.

      S-8 POS - AMYRIS, INC. (0001365916) (Filer)

      2/9/24 9:12:50 PM ET
      $AMRS
      Major Chemicals
      Industrials

    $AMRS
    Financials

    Live finance-specific insights

    See more
    • AMYRIS TO HOST FIRST QUARTER 2023 FINANCIAL RESULTS CONFERENCE CALL ON MAY 9

      EMERYVILLE, Calif., May 2, 2023 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that it will issue its financial results for the first quarter ended March 31, 2023, on the afternoon of Tuesday, May 9, 2023, after closing of the financial markets. The company will hold a conference call and webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time), during which, John Melo, President

      5/2/23 8:00:00 AM ET
      $AMRS
      Major Chemicals
      Industrials
    • AMYRIS, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS

      Fourth quarter Consumer revenue of $52.8 million increased 64% over the prior year and was another record quarter. Core revenue of $75.8 million grew 17% over the prior yearFull year Consumer revenue of $176.9 million increased 92% and outperformed prestige beauty industry growth of 15%. Core revenue of $269.8 million grew 44% over prior yearUse of cash for operating and investing activities sequentially improved each quarter; Q4 2022 down $102 million versus Q1 2022Actions taken to simplify portfolio, streamline management structure and deliver efficienciesEMERYVILLE, Calif., March 15, 2023 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating th

      3/15/23 4:11:00 PM ET
      $AMRS
      Major Chemicals
      Industrials
    • AMYRIS TO HOST FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS CONFERENCE CALL ON MARCH 15, 2023

      EMERYVILLE, Calif., Feb. 28, 2023 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that it will issue its financial results for the fourth quarter and full year ended December 31, 2022, on the afternoon of Wednesday, March 15, 2023, after closing of the financial markets. The company will hold a conference call and webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time), during wh

      2/28/23 8:00:00 AM ET
      $AMRS
      Major Chemicals
      Industrials

    $AMRS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Amyris Inc. (Amendment)

      SC 13D/A - AMYRIS, INC. (0001365916) (Subject)

      1/5/24 4:22:57 PM ET
      $AMRS
      Major Chemicals
      Industrials
    • SEC Form SC 13D/A filed by Amyris Inc. (Amendment)

      SC 13D/A - AMYRIS, INC. (0001365916) (Subject)

      12/14/23 4:34:27 PM ET
      $AMRS
      Major Chemicals
      Industrials
    • SEC Form SC 13D/A filed by Amyris Inc. (Amendment)

      SC 13D/A - AMYRIS, INC. (0001365916) (Subject)

      10/16/23 4:41:27 PM ET
      $AMRS
      Major Chemicals
      Industrials

    $AMRS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AVITA Medical Appoints Nicole Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary

      VALENCIA, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced the appointment of Nicole Linda Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary, effective July 1, 2024. Ms. Kelsey has more than two decades of executive legal experience with expertise in M&A, securities, and governance, along with a strong track record building and leading global regulatory and compliance programs. Previously, she served as Chief Legal Officer and Secretary for Amyris, Inc. (NASDAQ:AMRS) and General Counse

      7/1/24 4:05:00 PM ET
      $RCEL
      $AMRS
      Medical/Dental Instruments
      Health Care
      Major Chemicals
      Industrials
    • AMYRIS ANNOUNCES OPERATIONAL AND FINANCIAL RESTRUCTURING TO ADVANCE STRATEGIC TRANSFORMATION

      Voluntary Chapter 11 Commenced to Finalize Consensual Go-Forward Plan for Amyris' Core Business $190 Million Financing Commitment from Foris Ventures to Support Day-to-Day Operations EMERYVILLE, Calif., Aug. 9, 2023 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS) ("Amyris" or the "Company"), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that it is moving forward with an operational and financial restructuring to further advance its ongoing strategic transformation and position the Company for long-term success.

      8/9/23 9:38:00 PM ET
      $AMRS
      Major Chemicals
      Industrials
    • AMYRIS ANNOUNCES CEO TRANSITION AND GLOBAL REDUCTION IN FORCE

      EMERYVILLE, Calif., June 26, 2023 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that John Melo has resigned from his role as President & Chief Executive Officer and a member of the Board of Directors, effective immediately. The Company's Board of Directors has appointed Han Kieftenbeld as Interim Chief Executive Officer. Mr. Kieftenbeld will remain as the Company's Chief Financial Officer. The Company also announced a global reduction in force as an important step towards its previously announce

      6/26/23 9:10:00 AM ET
      $AMRS
      Major Chemicals
      Industrials

    $AMRS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Amyris downgraded by Jefferies with a new price target

      Jefferies downgraded Amyris from Buy to Hold and set a new price target of $0.65 from $3.10 previously

      5/18/23 7:22:16 AM ET
      $AMRS
      Major Chemicals
      Industrials
    • Amyris downgraded by TD Cowen with a new price target

      TD Cowen downgraded Amyris from Outperform to Market Perform and set a new price target of $1.25 from $4.00 previously

      5/10/23 7:29:32 AM ET
      $AMRS
      Major Chemicals
      Industrials
    • Canaccord Genuity initiated coverage on Amyris with a new price target

      Canaccord Genuity initiated coverage of Amyris with a rating of Buy and set a new price target of $1.50

      4/28/23 7:13:42 AM ET
      $AMRS
      Major Chemicals
      Industrials

    $AMRS
    Leadership Updates

    Live Leadership Updates

    See more

    $AMRS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • AVITA Medical Appoints Nicole Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary

      VALENCIA, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced the appointment of Nicole Linda Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary, effective July 1, 2024. Ms. Kelsey has more than two decades of executive legal experience with expertise in M&A, securities, and governance, along with a strong track record building and leading global regulatory and compliance programs. Previously, she served as Chief Legal Officer and Secretary for Amyris, Inc. (NASDAQ:AMRS) and General Counse

      7/1/24 4:05:00 PM ET
      $RCEL
      $AMRS
      Medical/Dental Instruments
      Health Care
      Major Chemicals
      Industrials
    • AMYRIS ANNOUNCES CEO TRANSITION AND GLOBAL REDUCTION IN FORCE

      EMERYVILLE, Calif., June 26, 2023 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, today announced that John Melo has resigned from his role as President & Chief Executive Officer and a member of the Board of Directors, effective immediately. The Company's Board of Directors has appointed Han Kieftenbeld as Interim Chief Executive Officer. Mr. Kieftenbeld will remain as the Company's Chief Financial Officer. The Company also announced a global reduction in force as an important step towards its previously announce

      6/26/23 9:10:00 AM ET
      $AMRS
      Major Chemicals
      Industrials
    • AMYRIS ANNOUNCES APPOINTMENT OF ANA DUTRA TO BOARD OF DIRECTORS

      EMERYVILLE, Calif., Jan. 27, 2022 /PRNewswire/ -- Amyris, Inc. (NASDAQ:AMRS) ("Amyris"), a leading synthetic biotechnology company accelerating the world to sustainable consumption through its Lab-to-MarketTM operating platform, today announced the appointment of Ms. Ana Dutra as its newest independent member of the Amyris Board of Directors, effective January 21, 2022. "We are very pleased to welcome Ana as a new, independent director to Amyris," said John Melo, President and Chief Executive Officer of Amyris. "Ana brings decades of leadership, operational depth and highly re

      1/27/22 8:00:00 AM ET
      $AMRS
      Major Chemicals
      Industrials
    • SEC Form 3 filed by new insider White J. Scott

      3 - AMYRIS, INC. (0001365916) (Issuer)

      9/20/23 8:09:50 PM ET
      $AMRS
      Major Chemicals
      Industrials
    • SEC Form 3 filed by new insider Gund Philip J.

      3 - AMYRIS, INC. (0001365916) (Issuer)

      8/17/23 7:35:56 PM ET
      $AMRS
      Major Chemicals
      Industrials
    • SEC Form 3 filed by new insider Reiss M. Freddie

      3 - AMYRIS, INC. (0001365916) (Issuer)

      8/17/23 7:32:49 PM ET
      $AMRS
      Major Chemicals
      Industrials